LONG-TERM FOLLOW-UP RESULTS OF NEWLY DIAGNOSED, UNTREATED ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS IN TURKEY

Basit Öğe Kaydı
dc.contributor.authorAski, Vural
dc.contributor.authorIlhami, Berber
dc.contributor.authorAhmet, Sarici
dc.contributor.authorAli, Erkurt Mehmet
dc.contributor.authorEmin, Kaya
dc.contributor.authorIrfan, Kuku
dc.date.accessioned2024-08-04T20:50:53Z
dc.date.available2024-08-04T20:50:53Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: There are very few studies about long-term follow-up results of newly diagnosed, untreated adult primary immune thrombocytopenia (ITP) patients, and the results differ from each other. Also, no study has so far been conducted in Turkey. The aim of this study was to determine the number of newly diagnosed adult ITP patients whose treatment started, the time until the start of treatment, and the rate of patients who did not receive any treatment during the follow-up period. Materials and methods: A total of 205 newly diagnosed ITP patients were retrospectively evaluated in this study; primary treatment was applied to 126 patients (61.5%) after diagnosis, and 79 patients (38.5%) were followed without treatment. Results: After ITP diagnosis, corticosteroid therapy was started for various reasons at a mean of 20 months (1-60 months) of follow-up in 24 (30.4%) of 79 patients who were followed without treatment. In 12 (50%) of 24 patients who were treated, treatment was applied because platelet counts were lower than 30x109/L or due to surgery or childbirth (50%) although platelet counts were higher than 30x109/L. With the deepening of thrombocytopenia (<30x109/L), treatment was initiated in 12 patients until the mean time of 10 months (1-58 months), and treatment was started in 9 (75%) of these patients in the first 12 months. Conclusion: We demonstrated that the majority (70%) of newly diagnosed untreated ITP patients had no treatment indication during follow-up at 60 months. Although the thrombocyte count was over 30.000/mm3 in half of the patients who had treatment indications during the follow-up period, treatment was started due to other reasons (surgery, pregnancy, etc.).en_US
dc.identifier.doi10.19193/0393-6384_2021_6_482
dc.identifier.endpage3079en_US
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85120478701en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage3075en_US
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2021_6_482
dc.identifier.urihttps://hdl.handle.net/11616/100338
dc.identifier.volume37en_US
dc.identifier.wosWOS:000730138900023en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPrimer Immune Thrombocytopeniaen_US
dc.subjectITPen_US
dc.subjectHaematologyen_US
dc.subjectComplete Blood Counten_US
dc.subjectCorticosteroiden_US
dc.titleLONG-TERM FOLLOW-UP RESULTS OF NEWLY DIAGNOSED, UNTREATED ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS IN TURKEYen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu